There's a billionaire fight happening in an Oakland federal courtroom right now. The headlines are calling it Elon Musk versus Sam Altman—tech titans, AI drama, billions at stake. But here's what almost nobody is telling you: if Elon wins this case, the next phone call won't be from Silicon Valley. It'll be from the general counsel's office at every nonprofit hospital in America.

The question on trial isn't really about AI chatbots. It's whether a charity that took tax-deductible donations under the explicit promise of serving the public can quietly convert itself into a for-profit empire where insiders pocket the upside. That is the exact business model of the modern nonprofit hospital.

In this episode, I break down the numbers nobody talks about, the smoking gun study from Health Affairs, the three legal doctrines on trial, and what happens next—whether Musk wins, loses, or lands somewhere in between.

Watch on YouTube: https://youtu.be/gXCwinAwrMA

Read the full breakdown: https://open.substack.com/pub/danmccoymd/p/is-your-local-hospital-doing-exactly

A 6-month-old named KJ Muldoon just received the first personalized CRISPR gene therapy ever made — designed, manufactured, and administered for his exact mutation in six months. Nature named him to the Top 10 People Who Shaped Science of 2025.

The miracle is real. The financing model isn't.

Gene therapies run $2M to $3.5M each. Insurance contracts are annual. Gene therapy benefits last a lifetime. The employer who pays in year one rarely sees the savings — average commercial plan tenure is three years.

In this episode:

— Why the "gene therapy tsunami" narrative is overstated (EBRI's numbers tell a different story)

— The free-rider problem and why annual contracts can't price lifetime cures

— The concierge medicine paradox: we pay $3M to cure you, but won't pay $300/mo to keep you healthy

— Four financing models worth knowing for 2026: gene-therapy-specific stop-loss, outcomes-based agreements, risk-pooling platforms, and performance-based annuities

— How AI is compressing drug development timelines — and why that compounds the budget problem

We have 21st century cures and 20th century accounting. Eventually, one of those has to change.

Watch the full video: https://youtu.be/ap2XjNf3LN0

Read the Substack companion piece: https://open.substack.com/pub/danmccoymd/p/21st-century-cures-20th-century-accounting

Full sources and the deep dive: danmccoymd.substack.com

If you're a medical student picking a specialty in 2026, you're being asked to bet a decade and $300,000 in debt on a market nobody is teaching you to read.

This episode is the framework I wish someone had given me — plus the data nobody else is putting in front of med students.

In this episode:

• Why 76% of all FDA-cleared medical AI targets a single specialty — and why residency applications to it are still up 30%
• The four kinds of physician cognition (and why "AI replaces cognitive work" is the wrong frame entirely)
• Which specialties get repriced, restructured, or protected — and why psychiatry might be safer than radiology
• The 2026 CMS efficiency adjustment nobody is talking about — and why it's a ratchet, not a one-time cut
• What medical schools are (and aren't) doing to prepare the next generation of physicians for an AI-driven workforce

Watch the video version with charts and visuals: https://youtu.be/NETog9SBtZs

Full sources and the deep dive: danmccoymd.substack.com